Ambeed.cn

首页 / LDN-212854

LDN-212854 {[allProObj[0].p_purity_real_show]}

货号:A189348 同义名: BMP Inhibitor III

LDN-212854是一种骨形态发生蛋白 (BMP) 抑制剂,能够有效抑制 ALK2,IC50 为 1.3 nM,同时也抑制 ALK1 (IC50: 2.40 nM)。该化合物可用于研究进行性骨化纤维发育不良及相关癌症(如肝细胞癌 HCC)。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
LDN-212854 化学结构 CAS号:1432597-26-6
LDN-212854 化学结构
CAS号:1432597-26-6
LDN-212854 3D分子结构
CAS号:1432597-26-6
LDN-212854 化学结构 CAS号:1432597-26-6
LDN-212854 3D分子结构 CAS号:1432597-26-6
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

LDN-212854 纯度/质量文件 产品仅供科研

货号:A189348 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

LDN-212854 生物活性

靶点
  • ALK1

    ALK1, IC50:2.4 nM

  • TGFβRI/ALK5

    ALK5, IC50:9276 nM

  • ALK2

    ALK2, IC50:1.3 nM

  • ALK3

    ALK3, IC50:85.8 nM

  • ALK4

    ALK4, IC50:2133 nM

描述 The bone morphogenetic protein (BMP) signaling pathway has essential functions in development, homeostasis, and in the normal and pathophysiologic remodeling of tissues. BMPs initiate their signaling events through an interaction of their type I and type II receptors, both of which are transmembrane serine/threonine kinases. Seven type I receptors (a.k.a. activin receptor-like receptors; ALK1 to ALK7) and four type II receptors have been identified in mice and humans[3].. LDN-212854 is a selective and potent inhibitor of the BMP type I receptor kinases, with the IC50 values of 1.3 nM, 2.4 nM, 85.8 nM, 2133 nM, 9276 nM for ALK2, ALK1, ALK3, ALK4 and ALK5, respectively. LDN-212854 (IC50=37 nM) displayed low nanomolar potency in blocking the phosphorylation of SMAD1/5/8 induced by BMP7 (20 ng/mL, 30 min) in BMPR2−/− pulmonary vascular smooth muscle cells. ALK2Q207D transgenic mice model was used to evaluate the efficacy of LDN-212854 in vivo. After pretreating pericytes with 570nM LDN-212854 for 1 day, the osteoblast differentiation of pericytes from FOR hiPSCs was partly inhibited. Treatment with LDN-212854 on the dose of 6 mg/kg twice daily for 4 weeks can prevent the formation of heterotopic bone and preserved limb range of motion with minimal or no impairment in the majority of mice[4].
作用机制 LDN-212854 binds type I BMP receptor at the ATP-binding pocket. The pendant 5-quinoline group of LDN-212854 is predicted to form an alternative water-mediated hydrogen bond to the catalytic lysine (K235) of ALK2[5].

LDN-212854 细胞实验

Cell Line
Concentration Treated Time Description References
Mesenchymal cells 750 nM 12, 24, 48, 72, and 96 hr Evaluate the effect of LDN-212854 on mesenchymal cell proliferation, results show LDN-212854 significantly reduces cell proliferation Mol Ther. 2017 Aug 2;25(8):1974-1987.
Bone marrow mononuclear cells (BMMs) 1 μM 5 days LDN-212854 inhibits SMAD1/5/9 phosphorylation, thereby inhibiting osteoclastogenesis in caAcvr1 mutant cells. J Biol Chem. 2019 Nov 22;294(47):17818-17836.
Primary rat OPCs 0.18 μM 3 days To evaluate the effect of LDN-212854 on OPC differentiation in the presence of fibrinogen, results showed that LDN-212854 restored mature oligodendrocyte differentiation and reduced GFAP+ astrocyte formation. Brain. 2021 Sep 4;144(8):2291-2301.
HSG cells 0.1, 1.0 or 10 nM 4 days To investigate the effect of LDN-212854 on BMP6-induced loss of cell membrane water permeability. Results showed that LDN-212854 inhibited BMP6-induced RVD loss in a dose-dependent manner. Sci Rep. 2020 Feb 19;10(1):2967.
HSG cells 10 or 60 nM 24 hours To investigate the effect of LDN-212854 on BMP6-induced SMAD1/5/8 phosphorylation. Results showed that 60 nM LDN-212854 significantly reduced BMP6-induced SMAD1/5/8 phosphorylation. Sci Rep. 2020 Feb 19;10(1):2967.
C2C12 cells 500 nM 3 days To test the inhibitory effect of LDN-212854 on BMP2-induced alkaline phosphatase (ALP) activity, results showed that LDN-212854 significantly suppressed ALP activity. Stem Cell Res Ther. 2024 Apr 5;15(1):98.
Human mesenchymal stromal cells (MSCs) 500 nM 28 days To test the effect of LDN-212854 on MSC chondrogenesis in vitro, results showed that LDN-212854 mildly inhibited chondrogenesis but had limited effects on hypertrophy markers. Stem Cell Res Ther. 2024 Apr 5;15(1):98.

LDN-212854 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Mice Ntv-a;p53fl/fl mice Intraperitoneally 6 mg/kg Twice daily for 5 consecutive days (in vitro); twice a day until euthanasia endpoints were met (in vivo survival study) To evaluate the effect of LDN212854 on tumor growth and survival, results showed that LDN212854 significantly prolonged survival. Nat Commun. 2019 Mar 4;10(1):1023.
Mice Burn/tenotomy model Intraperitoneal injection 6 mg/kg Daily for 6 weeks Evaluate the effect of LDN-212854 on trauma-induced heterotopic ossification, results show LDN-212854 significantly reduces heterotopic ossification volume Mol Ther. 2017 Aug 2;25(8):1974-1987.
Mouse Acvr1[R206H]FlEx/+ conditional knock-in mice Subcutaneous injection 3 mg/kg Twice daily for 4 weeks LDN-212854 effectively suppressed spontaneous joint/ligament HO and injury-triggered intramuscular HO in Acvr1R206H mice, demonstrating selective ACVR1 inhibition abrogates cell-autonomous effects of mutant receptors in tendon and muscle progenitors. Sci Transl Med. 2016 Nov 23;8(366):366ra163
Mice C57BL/6.NOD-Aec1Aec2 mouse model Intraperitoneal injection 2.5 mg/kg Once daily for 24 days To investigate the effect of LDN-212854 on the restoration of salivary gland function in C57BL/6.NOD-Aec1Aec2 mice. Results showed that LDN-212854 treatment significantly increased salivary flow rate and reduced phosphorylation of SMAD1/5/8 and expression of ID3. Sci Rep. 2020 Feb 19;10(1):2967.
NCG mice HCC xenograft model Intraperitoneal injection 6 mg/kg Twice daily for 10-14 days LDN-212854 significantly suppressed HCC tumor growth and induced global RNA m6A methylation Int J Mol Sci. 2024 Jan 12;25(2):981.
NOD/SCID mice HCC xenograft model Intraperitoneal injection 6 mg/kg Twice daily for 10-14 days Inhibited HCC tumor growth and angiogenesis Int J Mol Sci. 2022 Jan 27;23(3):1475.

LDN-212854 动物研究

Dose Mice: 6 mg/kg[1] (i.p.)
Administration i.p.

LDN-212854 参考文献

[1]Mohedas AH, Xing X, et al. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013;8(6):1291-302.

[2]Williams E, Bullock AN. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone. 2017 Sep 12. pii: S8756-3282(17)30340-X.

[3]Luo J, Tang M, Huang J, He BC, Gao JL, Chen L, Zuo GW, Zhang W, Luo Q, Shi Q, Zhang BQ, Bi Y, Luo X, Jiang W, Su Y, Shen J, Kim SH, Huang E, Gao Y, Zhou JZ, Yang K, Luu HH, Pan X, Haydon RC, Deng ZL, He TC. TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J Biol Chem. 2010 Sep 17;285(38):29588-98

[4]Cai J, Orlova VV, Cai X, Eekhoff EMW, Zhang K, Pei D, Pan G, Mummery CL, Ten Dijke P. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva. Stem Cell Reports. 2015 Dec 8;5(6):963-970.

[5]Mohedas AH, Xing X, Armstrong KA, Bullock AN, Cuny GD, Yu PB. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013;8(6):1291-302.

LDN-212854 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.46mL

0.49mL

0.25mL

12.30mL

2.46mL

1.23mL

24.60mL

4.92mL

2.46mL

LDN-212854 技术信息

CAS号1432597-26-6
分子式C25H22N6
分子量 406.48
SMILES Code C12=C(C3=C4N=CC(C5=CC=C(N6CCNCC6)C=C5)=CN4N=C3)C=CC=C1N=CC=C2
MDL No. MFCD28099808
别名 BMP Inhibitor III
运输蓝冰
InChI Key BBDGBGOVJPEFBT-UHFFFAOYSA-N
Pubchem ID 60182388
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, sealed in dry, 2-8°C

溶解方案

DMSO: 30 mg/mL(73.8 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
方案 二
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。